News

Kevin O’Meara discusses Patient-Cetric 3.0 breakout session and the challenges of drug manufactures implementing Direct-to-Patient models.

A session investigates the drivers of these shortages and ways to mitigate them.

Breakout session explores how direct-to-patient models shorten the time to diagnosis and therapy to improve patient outcomes.

A case study explores a way to potentially transform commercial organizations, while driving revenue growth.

A panel uncovers how distribution channels are aligning commercialization efforts.

Conference keynote speech examines the industry’s critical developments of 2024 and offers a strategic outlook for next year.

A cohort study of cancer drugs analyzes where the priorities of pricing policies should lie.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Joe Lipari, director of product management, Systech, predicts the probability that these DSCSA compliance deadlines put forth by the FDA will be met.

The companies will be financially committing $1 and $3 billion into their respective manufacturing facilities.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Joe Lipari, director of product management, Systech, comments on what the repercussions are for failing to comply with the DSCSA.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Joe Lipari, director of product management, Systech, describes the latest state of DSCSA implementation guidelines.

A qualitative analysis consisting of patients, care partners, and oncology clinicians measures the sources of time burdens, along with how these impact various individuals.

Dr. Reddy’s immuno-oncology drug for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma will be marketed under the brand name Zytorvi.

The agreement provides PTC with $1 billion in cash once deal closes, and is centered around PTC518's development, manufacturing and commercialization.

A total of 140 companies are being placed on the Entity List, in an effort to limit China’s effectiveness in the sector.

The transaction reaffirms the CDMO’s interest in growth on a global scale.

Nicholas Saraceno offers an overview of the legislation and how it impacts the pharma supply chain.

The proposal aims to reduce out-of-pocket costs for a number of weight loss medications by 95%.

Why well-organized documentation is critical at every stage of the process.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Gaurav Gupta, managing director and head of R&D at Kotter, offers advice for effectively being able to adjust plans.

In the second part of this roundtable discussion, key opinion leaders discuss the potential technological challenges surrounding RFID, and the likelihood of not only utilizing this tech at the item level but for product security purposes as well.

The CDMO’s offerings will now feature automated fill-finish.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Gaurav Gupta, managing director and head of R&D at Kotter, comments on the specific technical and soft skills that are critical in order for pharma leaders and frontline employees to excel in an ever-changing industry landscape, while explaining why these skills are beneficial when it comes to being proactive in handling talent shortages.

Ryplazim is considered the first and only FDA-approved therapy specifically for the PLGD-1 indication.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Gaurav Gupta, managing director and head of R&D at Kotter, outlines the steps that pharma leaders should keep in mind to when combatting supply chain issues.

The CDMO's California facility welcomes new production suites, a revamp of its development labs, and more.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Gaurav Gupta, managing director and head of R&D at Kotter, details the types of regulatory pressures and factors surrounding rising R&D costs that will affect the pharmaceutical industry.

The media company utilized CMS data and worked with Medicare experts to pinpoint qualities that were highly valued to consumers.